Histidine

Histidine

SCHEMBL874925

N[C@@H](CO)C(=O)O.N[C@@H](Cc1c[nH]cn1)C(=O)O

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.43
CYP3A4 P08684 2/20 0.43
CYP1A2 P05177 1/20 0.42
PKM P14618 2/20 0.39
ALPI P09923 1/20 0.39
PTGS1 P23219 1/20 0.39
XIAP P98170 1/20 0.39
GRIA2 P42262 5/20 0.37
GRIA1 P42261 4/20 0.37
GRIA3 P42263 4/20 0.37
GRIA4 P48058 4/20 0.37
HSD17B10 Q99714 2/20 0.36
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 2/20 0.36
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36
BLM P54132 2/20 0.36
PMP22 Q01453 2/20 0.36
KMT2A Q03164 2/20 0.36
HIF1A Q16665 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Histidine SCHEMBL874923 1.00 SLC7A5 (0.43) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL7521151 0.94 SLC7A5 (0.39) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL22769647 0.94 SLC7A5 (0.39) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL3967555 0.94 SLC7A5 (0.39) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL163442 0.94 SLC7A5 (0.47) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL995910 0.94 SLC7A5 (0.47) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL8080341 0.94 SLC7A5 (0.47) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL3259 0.94 SLC7A5 (0.47) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL163443 0.94 SLC7A5 (0.47) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL388563 0.94 SLC7A5 (0.47) SLC7A5CYP3A4CYP1A2PKMALPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1794323-B1 IN VIVO INCORPORATION OF ALKYNYL AMINO ACIDS INTO PROTEINS IN EUBACTERIA SCRIPPS RESEARCH INST (US) 2014-08-06 EP claimed
US-20240197882-A1 HUMANIZED ANTI-SIALYL-TN GLYCAN ANTIBODIES AND USES THEREOF RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2024-06-20 US disclosed
EP-4326777-A1 HUMANIZED ANTI-SIALYL-TN GLYCAN ANTIBODIES AND USES THEREOF Ramot at Tel-Aviv University Ltd. (IL) 2024-02-28 EP disclosed
US-20240043561-A1 HUMANIZED ANTIBODIES AND FRAGMENTS THEREOF BINDING TO CARBOHYDRATE ANTIGENS AND USES THEREOF RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2024-02-08 US disclosed
EP-4251653-A1 HUMANIZED ANTIBODIES AND FRAGMENTS THEREOF BINDING TO CARBOHYDRATE ANTIGENS AND USES THEREOF Ramot at Tel-Aviv University Ltd. (IL) 2023-10-04 EP disclosed
US-20230174664-A1 ANTIBODIES TO CARBOHYDRATE ANTIGENS RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2023-06-08 US disclosed
US-20230058044-A1 CHIMERIC ANTIGEN RECEPTOR TO CARBOHYDRATE ANTIGENS UNIV RAMOT (IL) 2023-02-23 US disclosed
CN-115702892-A Application of serine in preparation of medicine for preventing and/or treating acute pancreatitis 四川大学华西医院 2023-02-17 CN disclosed
EP-4065605-A1 ANTIBODIES TO CARBOHYDRATE ANTIGENS Ramot at Tel-Aviv University Ltd. (IL) 2022-10-05 EP disclosed
WO-2022113066-A1 HUMANIZED ANTIBODIES AND FRAGMENTS THEREOF BINDING TO CARBOHYDRATE ANTIGENS AND USES THEREOF RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2022-06-02 WO disclosed
US-9783783-B2 Compositions and methods for the expansion of stem cells CORNELL UNIVERSITY (US) 2017-10-10 US disclosed
US-9321847-B2 Activatable toxin complexes comprising a cleavable inhibitory peptide RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2016-04-26 US disclosed
US-20150368613-A1 COMPOSITIONS AND METHODS FOR THE EXPANSION OF STEM CELLS CORNELL UNIVERSITY 2015-12-24 US disclosed
WO-2014120714-A1 COMPOSITIONS AND METHODS FOR THE EXPANSION OF STEM CELLS CORNELL UNIVERSITY (US) 2014-08-07 WO disclosed
EP-1794323-B1 IN VIVO INCORPORATION OF ALKYNYL AMINO ACIDS INTO PROTEINS IN EUBACTERIA SCRIPPS RESEARCH INST (US) 2014-08-06 EP disclosed
US-20130202598-A1 ACTIVATABLE TOXIN COMPLEXES COMPRISING A CLEAVABLE INHIBITORY PEPTIDE RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2013-08-08 US disclosed
WO-2012038950-A1 ACTIVATABLE TOXIN COMPLEXES COMPRISING A CLEAVABLE INHIBITORY PEPTIDE RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2012-03-29 WO disclosed
WO-2002006455-A2 REGULATION OF HUMAN AIRWAY TRYPSIN PROTEASE-LIKE ENZYME BAYER AKTIENGESELLSCHAFT (DE) 2002-01-24 WO disclosed
EP-1025241-A2 MULTIPLY-SUBSTITUTED PROTEASE VARIANTS GENENCOR INTERNATIONAL INC. (US) 2000-08-09 EP disclosed
WO-1999020770-A2 MULTIPLY-SUBSTITUTED PROTEASE VARIANTS GENENCOR INTERNATIONAL, INC. (US) 1999-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043561-A1 HUMANIZED ANTIBODIES AND FRAGMENTS THEREOF BINDING TO CARBOHYDRATE ANTIGENS AND USES THEREOF CD47, FCGR2A, FCGR3B SLC7A5 2932/4885CYP3A4 4394/4885CYP1A2 4810/4885
US-20230174664-A1 ANTIBODIES TO CARBOHYDRATE ANTIGENS SSB, FCGR3B, FCGR2A SLC7A5 2049/4885CYP3A4 4872/4885CYP1A2 4870/4885
US-20230058044-A1 CHIMERIC ANTIGEN RECEPTOR TO CARBOHYDRATE ANTIGENS CD47, FCGR2A, CD2 SLC7A5 2263/4885CYP3A4 4632/4885CYP1A2 4757/4885
US-20240197882-A1 HUMANIZED ANTI-SIALYL-TN GLYCAN ANTIBODIES AND USES THEREOF FUT5, SIGLEC7, CD44 SLC7A5 1097/4885CYP3A4 2740/4885CYP1A2 4607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.